عرض بسيط للتسجيلة

المؤلفLaila, Shafei
المؤلفBashir, Shaima
المؤلفChan, Esther W.
المؤلفAbushanab, Dina
المؤلفHamad, Anas
المؤلفAl-Badriyeh, Daoud
تاريخ الإتاحة2024-05-20T10:36:43Z
تاريخ النشر2024-03-26
اسم المنشورCurrent Problems in Cancer
المعرّفhttp://dx.doi.org/10.1016/j.currproblcancer.2024.101076
الاقتباسShafei, L., Bashir, S., Chan, E. W., Abushanab, D., Hamad, A., & Al-Badriyeh, D. (2024). Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis. Current Problems in Cancer, 50, 101076.
الرقم المعياري الدولي للكتاب01470272
معرّف المصادر الموحدhttps://www.sciencedirect.com/science/article/pii/S0147027224000175
معرّف المصادر الموحدhttp://hdl.handle.net/10576/55204
الملخصPurposeSelinexor is a first-in-class, oral selective-inhibitor-of-nuclear-export, granted accelerated approval by FDA (2019) for relapsed and refractory multiple myeloma (RRMM). We sought to quantitatively summarize the selinexor efficacy and safety in RRMM. MethodsWe searched PubMed, EMBASE, CENTRAL, clinicaltrial.gov, and google scholar, until May 2023, studies about selinexor use in RRMM. The outcome measures of interest were primarily efficacy outcomes, in addition to safety outcomes. Random-effect model analyses were performed, at statistical significance of P<0.05, using the RevMan software. ResultsMeta-analyses of eleven included clinical trials yielded a significant 56.21% overall clinical benefit, 46.91% overall response, 4.89% complete response, 23.41% very good partial response, 24.68% partial response, and 28.06% stable disease rates with selinexor. Due to safety reasons, selinexor caused significant increase in discontinuation rate, 16.80%. Subgroup analyses demonstrated higher efficacy with selinexor plus dexamethasone and proteasome inhibitor combinations than with selinexor alone. The multiple myeloma type, high cytogenetic risk, refractory state, and advanced disease state did not affect performance. Risk of selection, performance, and detection biases were unclear in the included trials. ConclusionSelinexor led to significant positive responses with an acceptable safety profile in RRMM patients, despite higher rates of safety-related discontinuations. Selinexor-based combinations further enhanced response.
اللغةen
الناشرElsevier
الموضوعSelinexor [Mesh]
Multiple myeloma [MesH]
SINE compounds
Meta-analysis
العنوانEfficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
النوعArticle
رقم المجلد50
ESSN1535-6345
dc.accessType Full Text


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة